Method for differentiating dopaminergic neurons from stem cells
By combining non-adherent culture methods with specific signal transduction inhibitors and activators, dopaminergic neuronal progenitor cells can be differentiated, which solves the ethical and resource issues in the stem cell differentiation process, improves cell specificity and activity, and is suitable for the treatment of Parkinson's disease.
Patent Information
- Application Number
- CN202480039731.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-13
- Filing Date
- 2024-06-13
- Publication Date
- 2026-05-15
AI Technical Summary
Existing technologies for differentiating dopaminergic neurons from stem cells present ethical issues, risks of immune rejection, and inconsistencies in cell production. Furthermore, traditional methods are time-consuming and resource-intensive, making it difficult to effectively produce dopaminergic neurons suitable for the treatment of Parkinson's disease.
A non-adherent culture method was used to incubate and culture pluripotent stem cells in a combination of TGF-β/activin-Nodal signaling inhibitors, BMP signaling inhibitors, SHH signaling activators, and GSK3β signaling inhibitors, thereby differentiating them into dopaminergic neuronal progenitor cells and reducing the impact of substrate and reagent variability.
It improved the specificity and activity of dopaminergic neuronal progenitor cells, reduced serotonin production, shortened differentiation time, reduced resource consumption, and enhanced cell manufacturability and therapeutic efficacy.